TWi Pharma Regains US Rights to Products from Teva

TWi Pharma of Taiwan has reacquired US distribution rights to two of its products from Teva, which TWi will now market through its own US subsidiary. The two products are Megace® ES (megestrol acetate oral suspension), a treatment for weight loss, and Lidoderm® (lidocaine patch, 5%), a topical anesthetic. TWi makes difficult-to-make generic products, often with a controlled release delivery, with the US market as its primary target. More details.... Stock Symbols: (TW: 4180) (NYSE: TEVA) Share this with colleagues: // //   <br />